2020
DOI: 10.3389/fchem.2020.00485
|View full text |Cite
|
Sign up to set email alerts
|

Strategies to Investigate Ubiquitination in Huntington's Disease

Abstract: Many neurodegenerative disorders including Huntington's Disease are hallmarked by intracellular protein aggregates that are decorated by ubiquitin and different ubiquitin ligases and deubiquitinating enzymes. The protein aggregates observed in Huntington's Disease are caused by a polyglutamine expansion in the N-terminus of the huntingtin protein (Htt). Improving the degradation of mutant Htt via the Ubiquitin Proteasome System prior to aggregation would be a therapeutic strategy to delay or prevent the onset … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 97 publications
0
10
0
Order By: Relevance
“…In Huntington disease, poly-glutamine-expanded mHTT aggregates and accumulates 194 , presenting another difficult drug target that may be addressable by a PROTAC, as clearance of mHTT via the UPS pathway is thought to be beneficial for disease progression 195 . In fact, two small-molecule TPD strategies have been reported to lower mHTT levels: a small-molecule glue www.nature.com/nrd R e v i e w s 0123456789();: approach inducing the proximity between mHTT and microtubule-associated protein 1 light chain 3α (MAP1LC3α; also known as LC3) to target it to the autophagy pathway for degradation 196 ; and small-molecule PROTACs that recruit mHTT aggregates to E3 ligases from the IAP family, causing the proteasomal degradation of the mutant protein 197 .…”
Section: Neurology and Neurodegenerationmentioning
confidence: 99%
“…In Huntington disease, poly-glutamine-expanded mHTT aggregates and accumulates 194 , presenting another difficult drug target that may be addressable by a PROTAC, as clearance of mHTT via the UPS pathway is thought to be beneficial for disease progression 195 . In fact, two small-molecule TPD strategies have been reported to lower mHTT levels: a small-molecule glue www.nature.com/nrd R e v i e w s 0123456789();: approach inducing the proximity between mHTT and microtubule-associated protein 1 light chain 3α (MAP1LC3α; also known as LC3) to target it to the autophagy pathway for degradation 196 ; and small-molecule PROTACs that recruit mHTT aggregates to E3 ligases from the IAP family, causing the proteasomal degradation of the mutant protein 197 .…”
Section: Neurology and Neurodegenerationmentioning
confidence: 99%
“…Ubiquitination of the N-terminus of HTT is found to affect aggregation [ 22 ]. Moreover, MAPT and HTT appear to be targets for both the UPS and autophagy, with a key role for ubiquitin to target MAPT and HTT for degradation [ 23 , 24 ].These various results may indicate together that TRIM44-mediated MAPT and HTT aggregates clearance could base on its affinity to polyubiquitinated proteins. Therefore, we further isolated the aggregate and non-aggregate proteins using the differences in their solubility in NP-40 and SDS buffers and quantified their levels in cells.…”
Section: Resultsmentioning
confidence: 99%
“…A polyQ length lower than 35 does not cause HD, polyQ length of 35–39 may or may not be harmful, polyQ repeats of 40–60 causes HD in adults, whereas a polyQ length over 60 causes disease in the underage. Although mhtt protein is a large protein containing 3144 amino acid residues, it is proteolyzed into a number of N-terminal residues that accumulate in oligomers. There are different regions other than the polyQ domain that influence the aggregation property and several other structural and functional aspect of the protein. Figure shows the amino acid sequence of mhtt protein with regions like N-terminal part of the protein consisting of the exon1 Nt17 domain, the polyQ stretch and the polyproline (polyP) sequence. The polyQ region of the protein starts from the 18th residue.…”
Section: Huntington’s Disease (Hd)mentioning
confidence: 99%